Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 10/20 | 0.45 |
| ▸ | TPSD1 | Q9BZJ3 | 10/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 10/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22875087 | 0.98 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1THRBATM | |
| SCHEMBL12988236 | 0.95 | TPSAB1 (0.49) | TPSAB1TPSD1TPSG1HRH3F2 | |
| SCHEMBL22875085 | 0.91 | GAA (0.42) | TPSAB1TPSD1TPSG1THRBATM | |
| SCHEMBL22874719 | 0.83 | EPHX2 (0.39) | TPSAB1TPSD1TPSG1HRH3PRSS1 | |
| SCHEMBL26228162 | 0.81 | HRH3 (0.36) | TPSAB1TPSD1TPSG1HRH3 | |
| SCHEMBL12991729 | 0.80 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1EPHX1ALDH1A1 | |
| SCHEMBL13016393 | 0.80 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1EPHX1ALDH1A1 | |
| SCHEMBL12791455 | 0.80 | HSD11B1 (0.47) | TPSAB1TPSD1TPSG1L3MBTL1EPHX1 | |
| SCHEMBL8263030 | 0.79 | GAA (0.47) | TPSAB1TPSD1TPSG1THRBATM | |
| SCHEMBL12988207 | 0.78 | GPR119 (0.45) | HRH3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | TPSAB1 4136/4885TPSD1 4661/4885TPSG1 4341/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | TPSAB1 4321/4885TPSD1 4644/4885TPSG1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.